Skip to main content
Fig. 1 | Genome Medicine

Fig. 1

From: Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma

Fig. 1

In vitro TMZ screening of patient-derived glioblastoma (GBM) stem cell (GSC) predicts GBM prognosis. a TMZ sensitivity determination pipeline for patient-derived GSC. GR: growth rate; AUC: area under the conventional drug response curve; GSC: Glioblastoma Stem Cell; TMZ: temozolomide. b GR50 and AUC z-score comparison between MGMT methylated and un-methylated samples. Wilcoxon rank sum tests were performed for p-values (* P < 0.05). c, d Comparison of progression-free survival (c) and overall survival (d) between the TMZ-resistant (red) and TMZ-sensitive (blue) patients. The cohort was determined by TMZ screening in panel a. Sen, TMZ-sensitive; Res, TMZ-resistant. P-values were calculated by logrank test

Back to article page

Genome Medicine

ISSN: 1756-994X

Contact us